scholarly journals A Hot Spot for Systemic Lupus Erythematosus, but Not for Psoriatic Arthritis, Identified by Spatial Analysis Suggests an Interaction Between Ethnicity and Place of Residence

2013 ◽  
Vol 65 (6) ◽  
pp. 1579-1585 ◽  
Author(s):  
Mustafa Al-Maini ◽  
Thurarshen Jeyalingam ◽  
Patrick Brown ◽  
Jennifer J. Y. Lee ◽  
Lennon Li ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Psoriatic Arthritis ◽  
Spatial Analysis ◽  
Lupus Erythematosus ◽  
Hot Spot ◽  
Place Of Residence ◽  
Systemic Lupus

Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis

2007 ◽  
Vol 67 (4) ◽  
pp. 542-546 ◽  
Author(s):  
B Vander Cruyssen ◽  
L Nogueira ◽  
J Van Praet ◽  
D Deforce ◽  
D Elewaut ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Psoriatic Arthritis ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Human Fibrinogen ◽  
Peptide Antibody ◽  
Test Variability ◽  
Antibody Tests ◽  
Citrullinated Protein

Background:Different methods exist to demonstrate anti-citrullinated protein/peptide antibodies (ACPA).Aims:To evaluate discrepancy between four ACPA tests.Patients and methods:Population 1 consisted of patients with a new diagnostic problem, including 86 patients with rheumatoid arthritis (RA) and 450 patients without RA. Population 2 consisted of 155 patients with RA who had long-standing disease. Population 3 consisted of 188 patients with psoriatic arthritis and in population 4 there were 192 patients with systemic lupus erythematosus. Populations 1 and 2 were tested with the anti-human fibrinogen antibody (AhfibA) test, anti-CCP2 from Eurodiagnostica (CCP2-euro), anti-CCP2 from Pharmacia (CCP2-phar) and anti-CCP3 test by Inova (CCP3). Samples were annotated as discrepant if positive in one and negative in at least one other test. Each discrepant sample was re-analysed in a different run. Populations 3 and 4 were analysed in the CCP2-euro and AhFibA test.Results:In population 1, ACPA positivity was found in 17 of 450 (3.8%) patients without RA; 14 (82%) of these 17 samples were discrepant. In contrast, 61 of 86 (70.9%) patients with RA were ACPA positive of whom 18 of 61 (29.5%) were discrepant (70.9% vs. 29.5%, p<0.001). The discrepancies between tests could be partly attributed to borderline results, inter-assay discrepancy and inter-test variability. They were more prevalent in patients with systemic lupus erythematosus who were ACPA positive than in those with psoriatic arthritis who were ACPA positive.Conclusions:Discrepancy between different ACPA tests was observed attributable to the occurrence of borderline results, inter-assay variability and mainly to inter-test variability. The lowest inter-test discrepancy is observed between tests that use the same substrate.

Rheumatology

2020 ◽  
pp. 263-306
Author(s):  
Charlotte Frise ◽  
Sally Collins
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Lupus Erythematosus ◽  
Pregnant Patient ◽  
Systemic Lupus ◽  
Musculoskeletal Problems ◽  
In Pregnancy

This chapter covers rheumatic diseases in the pregnant patient. It gives background, clinical features, and management in the pregnant patient for rheumatoid arthritis, Sjögren’s syndrome, psoriatic arthritis, systemic lupus erythematosus, antiphospholipid syndrome, and ankylosing spondylitis among others. It also covers systemic sclerosis, osteoporosis, and other musculoskeletal problems. Medications and the use of biologics in pregnancy are also discussed, with reference to breastfeeding.

scholarly journals Comparison of cardiovascular risk burden in patients with psoriatic arthritis, ANCA-associated vasculitis and systemic lupus erythematosus

2021 ◽  
Author(s):  
Sorwe Mojtahed Poor ◽  
Michaela Köhm ◽  
Frank Behrens ◽  
Harald L. Burkhardt
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cardiovascular Risk ◽  
Psoriatic Arthritis ◽  
Risk Prediction ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Prediction Models ◽  
Left Ventricular ◽  
Systemic Lupus ◽  
Anca Associated Vasculitis

Abstract Background Cardiovascular risk factors and diseases represent the comorbidities with the highest prevalence in rheumatic diseases. Still, actual cardiovascular risk burden is often underestimated in current risk prediction models Methods To assess and compare traditional and nontraditional cardiovascular risk burden in patients with different rheumatic diseases, we analyzed demographical, clinical, laboratory, and non-invasive imaging data on patients with psoriatic arthritis in comparison with a cohort of ANCA-associated vasculitis and systemic lupus erythematosus in a cross-sectional design. Overall, we analyzed 138 patients. Results Data analysis revealed significant differences in traditional and nontraditional markers for cardiovascular disease risk as well as disparities in diastolic (6.67 % in PsA vs. 36% in AAV; OR 0.12 [0.03; 0.42], p < 0.05) and systolic left ventricular function (1.11% in PsA vs. 13.04% in SLE; OR 0.07 [0.005; 0.54], p < 0.05), whereas odds ratios for cardiovascular events did not differ significantly. Conclusion Our findings suggest that cardiovascular risk prediction algorithms should consider disease-specific disparities, which includes non-traditional cardiovascular risk burden, arguing for a patient-oriented risk assessment and consequently accurate risk stratification.

Locomotor

2019 ◽  
pp. 187-216
Author(s):  
Tanya M. Monaghan ◽  
James D. Thomas
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Lupus Erythematosus ◽  
Trigger Finger ◽  
Dupuytren’S Contracture ◽  
Systemic Lupus ◽  
Tophaceous Gout

This chapter concerns locomotive medicine, and covers rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, Paget’s disease, tophaceous gout, Marfan’s syndrome, systemic sclerosis, vasculitis, systemic lupus erythematosus, rickets, Dupuytren’s contracture, trigger finger, and Charcot’s joint.

scholarly journals Increased Prevalence of Systemic Lupus Erythematosus Comorbidity in Patients With Psoriatic Arthritis: A Population-Based Case-control Study

2020 ◽  
pp. jrheum.190940
Author(s):  
Danielle Korkus ◽  
Tal Gazitt ◽  
Arnon Dov Cohen ◽  
Ilan Feldhamer ◽  
Idit Lavi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Psoriatic Arthritis ◽  
Lupus Erythematosus ◽  
Conditional Logistic Regression ◽  
Fold Increase ◽  
Statin Treatment ◽  
Older Age ◽  
Incidence Density ◽  
Control Group ◽  
Systemic Lupus

Objective To assess the prevalence of systemic lupus erythematosus (SLE) in a psoriatic arthritis (PsA) cohort and to compare it to the general population using the database of a large healthcare provider. Methods We analyzed the database of a PsA cohort (2002–2017), matched for age and sex, with randomly selected controls for demographics, clinical and laboratory manifestations, and dispensed medications. Statistical analysis used t test and chi-square test as appropriate. In the PsA group, incidence density sampling was performed matching PsA patients without SLE as controls to each case of PsA with SLE by age and follow-up time. Univariable and multivariable conditional logistic regression analyses were used to assess factors affecting SLE development. Results The PsA and control groups consisted of 4836 and 24,180 subjects, respectively, with a median age of 56 ± 15 years, and of whom 53.8% were female. Eighteen patients (0.37%) in the PsA group and 36 patients (0.15%) in the control group were diagnosed with SLE (P = 0.001). SLE patients without PsA had higher anti-dsDNA and anticardiolipin antibodies. The usage of drugs with known potential to induce SLE was higher in the PsA than in the control group. Older age at PsA diagnosis, shorter PsA duration, and statin treatment were associated with SLE in PsA patients. Conclusion A 2.3-fold increase in the prevalence of SLE in PsA relative to the control group was found. Risk factors for SLE development included older age at PsA diagnosis, shorter PsA duration, and statin treatment. The association between PsA and SLE may affect treatment choices and medication development.

Sign in / Sign up

Export Citation Format

Share Document